Regeneron Pharmaceuticals (REGN) News Today → Man who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.” (From InvestorPlace) (Ad) Free REGN Stock Alerts $982.29 +14.31 (+1.48%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 7:09 AM | marketbeat.comRegeneron Pharmaceuticals Q1 Earnings TranscriptMay 19 at 4:18 AM | americanbankingnews.comLeonard S. Schleifer Sells 22,830 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 19 at 12:28 AM | marketbeat.comING Groep NV Has $24.87 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)ING Groep NV reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,311 shares of the biopharmaceutical company's stock afMay 18 at 8:56 AM | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 22,830 SharesMay 18 at 8:14 AM | msn.comRegeneron wins temporary restraining order preventing Eylea generic launch (update)May 17 at 9:00 PM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,019 shares of the biopharmaceMay 17 at 6:55 PM | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells $22,355,820.90 in StockRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) CEO Leonard S. Schleifer sold 22,830 shares of the company's stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total value of $22,355,820.90. Following the completion of the sale, the chief executive officer now directly owns 466,877 shares in the company, valued at approximately $457,179,964.71. The transaction was disclosed in a filing with the SEC, which is accessible through this link.May 17 at 1:45 PM | globenewswire.comMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024May 17 at 4:20 AM | insidertrades.comLeonard S. Schleifer Sells 25,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 16 at 10:00 PM | marketbeat.comBeacon Pointe Advisors LLC Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Beacon Pointe Advisors LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,786 shares of the biopMay 16 at 3:54 PM | businesswire.comKirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)May 16 at 7:30 AM | fool.comThese 2 No-Brainer Growth Stocks Are Breaking New GroundMay 16 at 7:15 AM | fool.comThese 2 No-Brainer Growth Stocks Are Breaking New GroundMay 16 at 6:44 AM | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by Evercore ISI to Strong-BuyMay 16 at 3:32 AM | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Earns Outperform Rating from Analysts at Evercore ISIMay 15, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 25,000 SharesRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company's stock, valued at $399,729,850. The transaction was disclosed in a legal filing with the SEC, which is available through this link.May 15, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 242,350 shares oMay 14, 2024 | msn.comEvercore ISI Group Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Outperform RecommendationMay 14, 2024 | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Has $102.16 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,336 shares of the bMay 14, 2024 | seekingalpha.comRegeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)May 14, 2024 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (REGN)May 14, 2024 | marketbeat.comEvercore ISI Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday. They set an "outperform" rating and a $1,150.00 price target on the stock.May 13, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Trimmed by Almanack Investment Partners LLC.Almanack Investment Partners LLC. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,600 shares of the biopharmaceutiMay 13, 2024 | markets.businessinsider.comRegeneron : Dupixent SBLA Accepted For FDA Priority Review For Adolescent Chronic RhinosinusitisMay 13, 2024 | globenewswire.comDupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)May 12, 2024 | marketbeat.comDimensional Fund Advisors LP Reduces Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Dimensional Fund Advisors LP reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 593,522 shares of the biopharMay 11, 2024 | marketbeat.comTeacher Retirement System of Texas Sells 3,591 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Teacher Retirement System of Texas reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 12.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,967 shares of the biopharmaceutical company's stock afterMay 10, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lifted by Montag A & Associates Inc.Montag A & Associates Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 505.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 927 shares of the biopharmaceutical company's stock after acquiring an additional 774May 10, 2024 | finance.yahoo.comRegeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past weekMay 10, 2024 | marketbeat.comWill the Biotech Sector Shift From Lagger to Leader?The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).May 10, 2024 | marketbeat.comWill the Biotech Sector Shift From Lagger to Leader? (REGN)The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.May 9, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Bronte Capital Management Pty Ltd.'s 3rd Largest PositionBronte Capital Management Pty Ltd. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 145,421 shares of the biopharmaceuticMay 8, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by National Pension ServiceNational Pension Service raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 186,310 shares of the biopharmaceutical companMay 8, 2024 | finance.yahoo.comLatest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 WeeksMay 8, 2024 | reuters.comRegeneron's experimental gene therapy improves hearing in one patientMay 7, 2024 | marketbeat.comEverpar Advisors LLC Makes New $782,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Everpar Advisors LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 890 shares of the biopharmaceutical company's stock, valued at apprMay 6, 2024 | globenewswire.comRegeneron Announces Investor Conference PresentationsMay 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regeneron on Strong Product Sales and Promising PipelineMay 6, 2024 | seekingalpha.comRegeneron: Dissecting The First Quarter Results And Regulatory SetbacksMay 6, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Los Angeles Capital Management LLCLos Angeles Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 663.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,345 shares ofMay 5, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by National Bank of Canada FINational Bank of Canada FI increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 161.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 116,227 shares of the biopharmaceutical comMay 4, 2024 | investorplace.com3 Biotech Stocks With the Potential to Make You an Overnight MillionaireMay 4, 2024 | marketbeat.comVictory Capital Management Inc. Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)Victory Capital Management Inc. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 92,891 shares of the biopharmaceutical company's stockMay 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regeneron on Strong Product Performance and Promising Pipeline DevelopmentsMay 4, 2024 | markets.businessinsider.comAssessing Regeneron Pharmaceuticals: Insights From 16 Financial AnalystsMay 4, 2024 | finance.yahoo.comRegeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...May 4, 2024 | finance.yahoo.comRegeneron Pharmaceuticals First Quarter 2024 Earnings: Misses ExpectationsMay 4, 2024 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Amalgamated BankAmalgamated Bank lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 25,856 shares of the biopharmaceutical company's stock after selling 1,191 shares during thMay 3, 2024 | investorplace.comShhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. REGN Media Mentions By Week REGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REGN News Sentiment▼0.640.42▲Average Medical News Sentiment REGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REGN Articles This Week▼3014▲REGN Articles Average Week Get Regeneron Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vertex Pharmaceuticals News GSK News Bristol-Myers Squibb News Sanofi News Zoetis News Pfizer News Takeda Pharmaceutical News Abbott Laboratories News Royalty Pharma News BeiGene News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REGN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesElon’s New Device is About to Shock the WorldInvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
